Small animal LTx is an invaluable model for investigating mechanisms of liver rejection. Heterotopic auxiliary liver transplantation with portal vein arterialization (HALT-PVA) in rats was introduced in 1968 by Lee and Edgington1when they reported using a recipient's renal vein and artery to re-vascularize a grafted auxiliary liver. Subsequently, Hess et al.2 enhanced the protocol with the mitigation of functional competition between the native and auxiliary livers by reducing the native and donor liver size along with reconstructing the donor bile duct connection, resulting in long-term graft survival. Further refinements were made with the introduction of cuff anastomosis3,4, and Schleimer et al.5 determined the optimal stent diameter for regulating blood flow to obtain physiological portal flow and avoid hyper- or hypo-perfusion of the graft. Other investigators developed significant alterations to the method by using the splenic6 or common iliac7 artery for graft blood supply, while some developed models that used only venous blood8 or only arterial blood via the hepatic artery9 to supply the auxiliary liver graft.
The present study hypothesized that functional competition from the native liver would not interfere with allograft rejection, so we developed a protocol based on the flow-regulated Schleimer model10 that did not include any size reduction of the native or auxiliary liver. The left side of the recipient was selected to locate the graft because it provided optimal orientation between the recipient's renal and donor liver vessels. Initially, we attempted biliary reconstruction via hepaticoduodenostomy but these trials simply confirmed Schleimer's assertion that "biliary drainage is the Achilles heel of liver transplantation"10. This prompted the development of a new technique where the bile duct is anastomosed end-to-end using a stent with the recipients' ureter, permitting the discharge of bile via the bladder. A noteworthy benefit of using a hepaticoureterostomy is that graft liver functionality can be monitored daily by observing the urine; a bile-producing liver graft colors the urine a bright yellow. Figure 1 represents the schematic overview of the HALT-PVA method.
An important advantage of heterotopic over orthotopic rat LTx relates to the absence of any anhepatic or total lower body ischemia time, which permits quicker and easier recoveries for heterotopic recipients. Additionally, LTx immunological studies utilizing orthotopic methods often rely on severe rejection or death of the recipient as an experimental endpoint, which is not the case with heterotopic transplants, where the animal remains healthy even if the allograft stops functioning due to rejection. Both of these features of the heterotopic method support principles of the international 3R's initiative (Replacement, Reduction, and Refinement)11, which promotes a framework for minimizing the pain, suffering, and distress experienced by research animals and improving their welfare.
The HALT-PVA model reported here is a practical and reliable method for investigating the mechanisms of hepatic allograft rejection in preclinical studies. This useful experimental technique helps overcome the considerable surgical demands and animal stress of orthotopic LTx in rats. In the future, we intend to use this method to investigate the mechanisms of acute immune rejection while exploring novel targets and therapeutic strategies to suppress hepatic allograft rejection.